Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-37440 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CEP-37440 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CEP-37440 | DRUG | CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily. Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined. |
Inclusion Criteria: * Patients must have histologic or cytologic evidence of a solid neoplasm for which no standard therapy is available, or have progressed despite standard therapy, or are intolerant to standard therapy. * Patients must have evidence of recurrent, locally advanced, or metastatic d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CEP-37440 is an investigational small molecule being studied for the treatment of solid tumors. It is being developed by Teva Pharmaceutical Industries Limited (TEVA). As of the available data, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
CEP-37440 is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential in treating solid tumors, though the exact mechanism of action is not specified.
CEP-37440 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker symbol TEVA. The drug is currently in Phase 1 clinical trials for solid tumors.
CEP-37440 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory bodies. The Phase 1 trial has been completed, and the drug is no longer in active clinical testing according to the available data.
CEP-37440 has been studied in one clinical trial, identified as NCT01922752. This Phase 1 trial was designed to determine the maximum tolerated dose of oral CEP-37440 in patients with advanced or metastatic solid tumors. The trial was completed and enrolled 32 participants in the United States.
CEP-37440 is not known to have any alternative names. It is an investigational small molecule being developed by Teva Pharmaceutical Industries Limited for the treatment of solid tumors. No other names for this drug have been reported.